Literature DB >> 31075545

Durable Clinical Response of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in trans-C797S to Combination Therapy of First- and Third-Generation EGFR Tyrosine Kinase Inhibitors.

Zhen Zhou1, Yi Zhao1, Shengping Shen1, Linping Gu1, Xiaomin Niu1, Yunhua Xu1, Tengfei Zhang2, Jianxing Xiang2, Xinru Mao2, Shun Lu3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31075545     DOI： 10.1016/j.jtho.2019.04.020

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  9 in total

Review 1.  Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.

Authors:  Alissa J Cooper; Lecia V Sequist; Jessica J Lin
Journal:  Nat Rev Clin Oncol       Date:  2022-05-09       Impact factor: 65.011

2.  Two case reports of non-small cell lung cancer patients harboring acquired EGFR T790M-cis-C797S benefit from immune checkpoint inhibitor combined with platinum-based doublet chemotherapy.

Authors:  Zizheng Song; Guanying Ren; Ling Hu; Xiaolei Wang; Jin Song; Youchao Jia; Guofa Zhao; Aimin Zang; Haiwei Du; Ying Sun; Xiaopeng Zhao
Journal:  Ann Transl Med       Date:  2022-06

3.  Primary Resistance to Combination Therapy with First- and Third-Generation EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in Trans-C797S Mutations with Co-Occurring CTNNB1 Alteration.

Authors:  Jianxin Chen; Junhui Wang; Xilin Wu
Journal:  Onco Targets Ther       Date:  2020-07-09       Impact factor: 4.147

Review 4.  Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors.

Authors:  Xiaojing Du; Biwei Yang; Quanlin An; Yehuda G Assaraf; Xin Cao; Jinglin Xia
Journal:  Innovation (Camb)       Date:  2021-04-03

Review 5.  Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.

Authors:  Lei Zhong; Yueshan Li; Liang Xiong; Wenjing Wang; Ming Wu; Ting Yuan; Wei Yang; Chenyu Tian; Zhuang Miao; Tianqi Wang; Shengyong Yang
Journal:  Signal Transduct Target Ther       Date:  2021-05-31

6.  Patterns and Treatment Strategies of Osimertinib Resistance in T790M-Positive Non-Small Cell Lung Cancer: A Pooled Analysis.

Authors:  Chunsheng Wang; Kewei Zhao; Shanliang Hu; Minghuan Li; Yipeng Song
Journal:  Front Oncol       Date:  2021-03-02       Impact factor: 6.244

Review 7.  Acquired Mechanisms of Resistance to Osimertinib-The Next Challenge.

Authors:  Alejandro Ríos-Hoyo; Laura Moliner; Edurne Arriola
Journal:  Cancers (Basel)       Date:  2022-04-12       Impact factor: 6.575

Review 8.  "Sandwich" Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected Patients.

Authors:  Guoqing Zhang; Beibei Yan; Yanan Guo; Hang Yang; Jindong Li
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738

9.  WX-0593 combined with an epithelial growth factor receptor (EGFR) monoclonal antibody in the treatment of xenograft tumors carrying triple EGFR mutations.

Authors:  Qingmei Zheng; Dongmei Chen; Xinmei Wang; Yingying Yang; Shuyong Zhao; Xin Dong; Cuicui Ma; Xin Zhang; Huicheng Duan; Yan Sun; Shansong Zheng
Journal:  Ann Transl Med       Date:  2022-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.